ErbB receptors: Directing key signaling networks throughout life

被引:497
作者
Holbro, T [1 ]
Hynes, NE [1 ]
机构
[1] Friedrich Miescher Inst Biomed Res, CH-4002 Basel, Switzerland
关键词
D O I
10.1146/annurev.pharmtox.44.101802.121440
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The epidermal growth factor (EGF)-related peptides bind the ErbB receptors, inducing the formation of different homo- and heterodimers. Receptor dimerization promotes activation of the intrinsic kinase, leading to phosphorylation of specific tyrosines located in the ErbB's cytoplasmic region. These phosphorylated residues serve as docking sites for a variety of signaling molecules whose recruitment stimulates intracellular signaling cascades, which ultimately control diverse genetic programs. Particular ligand-receptor complexes have essential roles in embryonic development as well as in the adult. Finally, ErbB receptors are being pursued as therapeutic targets because aberrant ErbB activity has been observed in many human cancers. In this review, we discuss these data in more detail, illustrating the importance of tightly regulated ErbB signaling throughout life.
引用
收藏
页码:195 / 217
页数:25
相关论文
共 149 条
  • [1] Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
    Agus, DB
    Akita, RW
    Fox, WD
    Lewis, GD
    Higgins, B
    Pisacane, PI
    Lofgren, JA
    Tindell, C
    Evans, DP
    Maiese, K
    Scher, HI
    Sliwkowski, MX
    [J]. CANCER CELL, 2002, 2 (02) : 127 - 137
  • [2] Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition
    Albanell, J
    Rojo, F
    Averbuch, S
    Feyereislova, A
    Mascaro, JM
    Herbst, R
    LoRusso, P
    Rischin, D
    Sauleda, S
    Gee, J
    Nicholson, RI
    Baselga, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) : 110 - 124
  • [3] ALIMANDI M, 1995, ONCOGENE, V10, P1813
  • [4] Alroy I, 1999, MOL CELL BIOL, V19, P1961
  • [5] ErbB2 is required for muscle spindle and myoblast cell survival
    Andrechek, ER
    Hardy, WR
    Girgis-Gabardo, AA
    Perry, RLS
    Butler, R
    Graham, FL
    Kahn, RC
    Rudnicki, MA
    Muller, WJ
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (13) : 4714 - 4722
  • [6] Tyrosine kinase inhibitors-ZD1839 (Iressa)
    Arteaga, CL
    Johnson, DH
    [J]. CURRENT OPINION IN ONCOLOGY, 2001, 13 (06) : 491 - 498
  • [7] Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy
    Asakura, M
    Kitakaze, M
    Takashima, S
    Liao, Y
    Ishikura, F
    Yoshinaka, T
    Ohmoto, H
    Node, K
    Yoshino, K
    Ishiguro, H
    Asanuma, H
    Sanada, S
    Matsumura, Y
    Takeda, H
    Beppu, S
    Tada, M
    Hori, M
    Higashiyama, S
    [J]. NATURE MEDICINE, 2002, 8 (01) : 35 - 40
  • [8] Trastuzumab in the treatment of non-small cell lung cancer
    Azzoli, CG
    Krug, LM
    Miller, VA
    Kris, MG
    Mass, R
    [J]. SEMINARS IN ONCOLOGY, 2002, 29 (01) : 59 - 65
  • [9] The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer
    Bartlett, JMS
    Langdon, SP
    Simpson, BJB
    Stewart, M
    Katsaros, D
    Sismondi, P
    Love, S
    Scott, WN
    Williams, ARW
    Lessells, AM
    Macleod, KG
    Smyth, JF
    Miller, WR
    [J]. BRITISH JOURNAL OF CANCER, 1996, 73 (03) : 301 - 306
  • [10] Baselga J, 1998, CANCER RES, V58, P2825